Latest News and Press Releases

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four...

REYKJAVIK, ISLAND och LONDON, UK (1 juli 2025) — Alvotech (NASDAQ: ALVO), ett globalt biofarmaceutiskt företag som specialiserar sig på utveckling och tillverkning av biosimilära läkemedel för...

REYKJAVÍK og LONDON, BRETLANDI (1. júlí 2025) - Alvotech (NASDAQ: ALVO) og Advanz Pharma tilkynntu í dag að félögin hafi gert með sér samning um markaðssetningu AVT10 í Evrópu. AVT10 er hliðstæða við...

REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and...

REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

Lenders have reduced the rate of interest on Alvotech's loan facility reflecting sustained operational improvements and strengthened financial performance

REYKJAVIK, ISLAND (26 juni 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, ”Bolaget”), ett globalt biofarmaceutiskt företag som specialiserar sig på utveckling och tillverkning av biosimilära läkemedel för...

REYKJAVIK (26. júní 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að bandaríska eignastýringarfyrirtækið GoldenTree Asset Management hafi boðist til að lækka vexti á langtímaskuldum...

REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of...